Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Arcturus Therapeutics (ARCT) Stock Price & Analysis
1,377 Followers
ARCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.52 - $43.81
Previous Close$25.98
Volume327.98K
Average Volume (3M)485.22K
Market Cap
$699.26M
Enterprise Value$433.16M
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$25.91M
Price to Earnings (P/E)-24.9
Beta2.10
Next Earnings
May 06, 2024EPS Estimate
-$1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding26,915,243
10 Day Avg. Volume570,546
30 Day Avg. Volume485,224
Standard Deviation0.32
R-Squared0.19
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.51
Price to Sales (P/S)22.66
Price to Cash Flow (P/CF)-277.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit2.60
Enterprise Value/Ebitda-17.37
Forecast
1Y Price Target
$70.00Price Target Upside158.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Arcturus Therapeutics News
PremiumCompany Announcements
Arcturus Therapeutics’ Kostaive® Vaccine Succeeds in Phase III
PremiumStock Analysis & Ideas
ARCT: Why Have Analysts Rated this Small-Cap Biotech Stock a “Strong Buy”?Bulls Say, Bears Say
Bulls Say
Drug Safety And TolerabilityARCT-810 was noted to be generally well-tolerated with no serious or severe adverse events, dose-limiting toxicities, or concerns for vitals, ECG or labs.
Treatment ConvenienceThe mRNA terminal half-life of ARCT-810 supports the potential for dosing every two weeks, which could offer convenient treatment scheduling.
Vaccine Market PositionKostaive's potential to become a prominently used COVID-19 vaccine and booster in Japan given its superior and durable immunogenicity compared to Comirnaty.
Bears Say
Drug Efficacy And Safety ConcernsKey risks to the analyst's rating and price target include unforeseen safety or tolerability issues with their mRNA drugs and potential delays to expected timelines.
Market Demand And CompetitionThe main reasons for the Underperform rating include skepticism about substantial orders of Kostaive from Japan and a lack of competitive data for Arcturus' non-vaccine agents.
Regulatory And Market DynamicsVaccinations for healthy people under the age of 65 will be voluntary and not subsidized by the government, potentially affecting the uptake rate.
---
Ownership Overview
13.92% Insiders
32.93% Mutual Funds
35.79% Other Institutional Investors
17.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $17.52 and its highest was $43.81 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Currently, no data Available
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 11 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.992 by $0.672.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -$1.23.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 26,915,243 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.992. Following the earnings report the stock price went down -0.887%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 65M.
---
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.00 (158.68% Upside)
$70.00 (158.68% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 150.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.11%
12-Months-Change
Fundamentals
Return on Equity
-9.69%
Trailing 12-Months
Asset Growth
-4.66%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
---
ARCT Earnings Call
Q4 2024
0:00 / 0:00
---
ARCT Stock 12 Months Forecast
Average Price Target
$70.00
▲(158.68% Upside)
Technical Analysis
BioNTech SE
―
Crispr Therapeutics AG
―
Inovio Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+80.49%
reiterated a sell rating 12 months ago
Copying Madhu Kumar's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +80.49% per trade.
---